Amphetamines are the second most-used illicit drugs worldwide following cannabis. With an approved treatment lacking for amphetamine or metamphetamine dependence, and a rise in hospitalization and death related to these cases, the investigation for effective pharmacologic therapies has gained pace. A 12-year-long Swedish cohort study evaluated the effectiveness of 17 pharmacologic treatments in 13,965 individuals aged 16 to 64 years with this disorder. Patients with schizophrenia and bipolar disorder were excluded.
Their major finding was related to the ADHD drug lisdexamfetamine . The risk of hospitalization and death due to this disorder was reduced by 18% and 14% respectively during periods of lisdexamfetamine use as compared to periods without it. Prescription of benzodiazepine use was associated with poor outcomes. Lisdexamfetamine, which is approved to treat ADHD as well as…
